Research.Patient.info
Relapsed/Refractory Mantle Cell Lymphoma research hub
2 indexed studies · 0 currently recruiting
- ongoing, recruitingTherapeutic exploratory (Phase II)
A Randomized, Controlled, Open-label, Multicenter, Inferentially Seamless Phase 2/3 Study of Ibrutinib in Combination With Rituximab Versus Physician’s Choice of Lenalidomide Plus Rituximab or Bortezomib Plus Rituximab in Participants with Relapsed or Refractory Mantle Cell Lymphoma
This study looks at new treatments for a type of blood cancer called mantle cell lymphoma that has come back or hasn't responded to earlier treatments. We're comparing a drug named Ibrutinib with standard treatments like Lenalidomide or Bortezomib, all given with Rituximab, to see which works best.
Czechia · Spain · Poland - ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-X19 in Subjects with Relapsed/Refractory Mantle Cell Lymphoma (ZUMA-2)
This study is looking at a new treatment called KTE-X19 for a type of cancer called Mantle Cell Lymphoma. It's for people whose cancer has come back or hasn't responded to previous treatments. Researchers want to see how well the new treatment shrinks the cancer.
France · Spain · Germany